Bookbot

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action

En savoir plus sur le livre

The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.

Achat du livre

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action, A.C.B. Cato, H. Schacke, K. Asadullah

Langue
Année de publication
2002
product-detail.submit-box.info.binding
(rigide)
Nous vous informerons par e-mail dès que nous l’aurons retrouvé.

Modes de paiement

Personne n'a encore évalué .Évaluer

Titre
Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action
Langue
Anglais
Éditeur
Springer
Publié
2002
Format
rigide
Pages
384
ISBN10
3540432299
ISBN13
9783540432296
Séries
Description
The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.